S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
S&P 500   4,262.54 (-0.59%)
DOW   33,294.61 (-0.64%)
QQQ   358.92 (+0.18%)
AAPL   172.93 (+1.00%)
MSFT   318.85 (+0.98%)
META   303.89 (+1.23%)
GOOGL   133.02 (+1.65%)
AMZN   128.75 (+1.28%)
TSLA   249.12 (-0.44%)
NVDA   444.27 (+2.13%)
NIO   8.73 (-3.43%)
BABA   86.14 (-0.69%)
AMD   101.91 (-0.89%)
T   14.71 (-2.06%)
F   12.27 (-1.21%)
MU   67.25 (-1.15%)
CGC   0.73 (-6.16%)
GE   108.61 (-1.75%)
DIS   81.31 (+0.32%)
AMC   8.09 (+1.25%)
PFE   33.71 (+1.63%)
PYPL   58.51 (+0.09%)
NFLX   379.28 (+0.44%)
NASDAQ:CRIS

Curis (CRIS) Stock Forecast, Price & News

$5.80
-0.79 (-11.99%)
(As of 02:18 PM ET)
Compare
Today's Range
$5.75
$6.57
50-Day Range
$7.60
$131.80
52-Week Range
$5.75
$20.00
Volume
69,224 shs
Average Volume
20,851 shs
Market Capitalization
$34.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.00

Curis MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
1,435.8% Upside
$90.00 Price Target
Short Interest
Bearish
22.58% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.20mentions of Curis in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($9.33) to ($8.40) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars

Medical Sector

838th out of 969 stocks

Biological Products, Except Diagnostic Industry

140th out of 161 stocks


CRIS stock logo

About Curis (NASDAQ:CRIS) Stock

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with solid tumors and lymphomas; and CA-327, a pre-clinical development candidate, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma; and Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

CRIS Price History

CRIS Stock News Headlines

Curis (NASDAQ:CRIS) Hits New 52-Week Low at $6.00
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Curis Reaches New 52-Week High (CRIS)
Curis (NASDAQ:CRIS) Given "Buy" Rating at HC Wainwright
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Analyst Ratings for Curis
Expert Ratings for Curis
Curis: Q2 Earnings Snapshot
Curis Provides Second Quarter 2023 Business Update
Curis launches ~$15.1M registered direct offering
Curis: FDA Removes Partial Clinical Hold On TakeAim Leukemia Study
See More Headlines
Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

CRIS Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
11/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CRIS
CUSIP
23126910
Employees
51
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$90.00
High Stock Price Forecast
$120.00
Low Stock Price Forecast
$60.00
Forecasted Upside/Downside
+1,351.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-56,670,000.00
Net Margins
-471.71%
Pretax Margin
-471.71%

Debt

Sales & Book Value

Annual Sales
$10.16 million
Book Value
$9.66 per share

Miscellaneous

Free Float
5,602,000
Market Cap
$36.52 million
Optionable
Optionable
Beta
3.04

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. James E. DentzerMr. James E. Dentzer (Age 56)
    Pres, CEO & Director
    Comp: $912.29k
  • Ms. Diantha Duvall CPA (Age 51)
    M.B.A., CFO, Treasurer, Assistant Sec., Principal Financial Officer & Principal Accounting Officer
    Comp: $588.95k
  • Mr. Mark W. Noel (Age 64)
    VP of Technology Management & Intellectual Property
  • Ms. Elif McDonald
    VP of Investor Relations & Corp. Communications
  • Dr. Reinhard Wilhelm von Roemeling M.D.
    Sr. VP of Clinical Devel.
  • Dr. Jonathan B. Zung Ph.D. (Age 58)
    Chief Devel. Officer













CRIS Stock - Frequently Asked Questions

Should I buy or sell Curis stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings
or view top-rated stocks.

What is Curis' stock price forecast for 2023?

2 equities research analysts have issued 12 month price objectives for Curis' shares. Their CRIS share price forecasts range from $60.00 to $120.00. On average, they expect the company's share price to reach $90.00 in the next twelve months. This suggests a possible upside of 1,351.6% from the stock's current price.
View analysts price targets for CRIS
or view top-rated stocks among Wall Street analysts.

How have CRIS shares performed in 2023?

Curis' stock was trading at $11.00 at the beginning of the year. Since then, CRIS stock has decreased by 43.6% and is now trading at $6.1999.
View the best growth stocks for 2023 here
.

Are investors shorting Curis?

Curis saw a increase in short interest in September. As of September 15th, there was short interest totaling 1,330,000 shares, an increase of 14.7% from the August 31st total of 1,160,000 shares. Based on an average trading volume of 324,500 shares, the short-interest ratio is presently 4.1 days.
View Curis' Short Interest
.

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 8th 2023.
View our CRIS earnings forecast
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) issued its quarterly earnings data on Thursday, August, 3rd. The biotechnology company reported ($2.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($2.40). The biotechnology company earned $2.20 million during the quarter, compared to analysts' expectations of $2.57 million. Curis had a negative trailing twelve-month return on equity of 116.63% and a negative net margin of 471.71%.

When did Curis' stock split?

Shares of Curis reverse split on the morning of Friday, September 29th 2023. The 1-20 reverse split was announced on Friday, September 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, September 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $6.20.

How much money does Curis make?

Curis (NASDAQ:CRIS) has a market capitalization of $36.52 million and generates $10.16 million in revenue each year. The biotechnology company earns $-56,670,000.00 in net income (profit) each year or ($10.00) on an earnings per share basis.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.

This page (NASDAQ:CRIS) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -